EXCLUSIVE LICENSE AND BAILMENT AGREEMENT BETWEEN 4D MOLECULAR THERAPEUTICS, LLC AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR ADENO-ASSOCIATED VIRUS VARIANTS FOR ENHANCED GENE DELIVERY IN THE PRESENCE OF NEUTRALIZING ANTIBODIESExclusive License and Bailment Agreement • December 7th, 2020 • 4D Molecular Therapeutics Inc. • Biological products, (no disgnostic substances) • California
This exclusive license agreement (“Agreement”) is effective December 19, 2013 (“Effective Date”), by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347 (“REGENTS”) and 4D MOLECULAR THERAPEUTICS LLC, a Delaware limited liability company having a principal place of business at 19 Rima Court, Danville, CA 94526 (“LICENSEE”). The parties agree as follows:
EXCLUSIVE LICENSE AND BAILMENT AGREEMENT BETWEEN 4D MOLECULAR THERAPEUTICS, LLC AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FOR ADENO-ASSOCIATED VIRUS SEROTYPE 2 (AAV2) CAPSID MUTANTS WITH NOVEL PROPERTIES FOR ENHANCED PERFORMANCE FOR GENE THERAPYExclusive License and Bailment Agreement • December 7th, 2020 • 4D Molecular Therapeutics Inc. • Biological products, (no disgnostic substances) • California
This exclusive license agreement (“Agreement”) is effective December 19, 2013 (“Effective Date”), by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607-5200, acting through its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347 (“REGENTS”) and 4D MOLECULAR THERAPEUTICS LLC, a Delaware limited liability company having a principal place of business at 19 Rima Court, Danville, CA 94526 (“LICENSEE”). The parties agree as follows:
EXCLUSIVE LICENSE AND BAILMENT AGREEMENT BETWEEN AVALANCHE BIOTECHNOLOGIES, INC. AND THE REGENTS OF THE UNIVERSITY OF CALIFORNIA FORExclusive License and Bailment Agreement • March 6th, 2019 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
This exclusive license agreement (“Agreement”) is effective June 17, 2013 (“Effective Date”), by and between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation, whose legal address is 1111 Franklin Street, 12th Floor, Oakland, California 94607- 5200, acting through its Office of Technology Licensing, at the University of California, Berkeley, 2150 Shattuck Avenue, Suite 510, Berkeley, CA 94704-1347 (“REGENTS”) and AVALANCHE BIOTECHNOLOGIES, INC., a Delaware corporation having a principal place of business at 665 Third Street, Suite 250, San Francisco, CA 94107 (“LICENSEE”). The parties agree as follows:
EXCLUSIVE LICENSE AND BAILMENT AGREEMENT BETWEEN -------------------------------------------------- BRIGHAM YOUNG UNIVERSITY AND BIOPULSE, INC. --------------------------------------------- 1 Definitions . . . . . . . . . . . . . . . . . . . . . . . ....Exclusive License and Bailment Agreement • December 21st, 2000 • Bio Pulse International Inc • Services-social services • Utah
